240 related articles for article (PubMed ID: 19372587)
1. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.
Hawthorne VS; Huang WC; Neal CL; Tseng LM; Hung MC; Yu D
Mol Cancer Res; 2009 Apr; 7(4):592-600. PubMed ID: 19372587
[TBL] [Abstract][Full Text] [Related]
2. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
[TBL] [Abstract][Full Text] [Related]
3. Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2.
Diaz Flaqué MC; Vicario R; Proietti CJ; Izzo F; Schillaci R; Elizalde PV
Steroids; 2013 Jun; 78(6):559-67. PubMed ID: 23178160
[TBL] [Abstract][Full Text] [Related]
4. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
5. NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress.
Clark DW; Mitra A; Fillmore RA; Jiang WG; Samant RS; Fodstad O; Shevde LA
Curr Cancer Drug Targets; 2008 Aug; 8(5):421-30. PubMed ID: 18690848
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.
Tan M; Jing T; Lan KH; Neal CL; Li P; Lee S; Fang D; Nagata Y; Liu J; Arlinghaus R; Hung MC; Yu D
Mol Cell; 2002 May; 9(5):993-1004. PubMed ID: 12049736
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.
Yu D; Jing T; Liu B; Yao J; Tan M; McDonnell TJ; Hung MC
Mol Cell; 1998 Nov; 2(5):581-91. PubMed ID: 9844631
[TBL] [Abstract][Full Text] [Related]
8. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
Choi YH; Yoo YH
Oncol Rep; 2012 Dec; 28(6):2163-9. PubMed ID: 23023313
[TBL] [Abstract][Full Text] [Related]
9. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.
Lu J; Tan M; Huang WC; Li P; Guo H; Tseng LM; Su XH; Yang WT; Treekitkarnmongkol W; Andreeff M; Symmans F; Yu D
Clin Cancer Res; 2009 Feb; 15(4):1326-34. PubMed ID: 19228734
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
12. Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.
Proietti CJ; Izzo F; Díaz Flaqué MC; Cordo Russo R; Venturutti L; Mercogliano MF; De Martino M; Pineda V; Muñoz S; Guzmán P; Roa JC; Schillaci R; Elizalde PV
Mol Endocrinol; 2015 Oct; 29(10):1468-85. PubMed ID: 26340407
[TBL] [Abstract][Full Text] [Related]
13. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.
Shackleford TJ; Zhang Q; Tian L; Vu TT; Korapati AL; Baumgartner AM; Le XF; Liao WS; Claret FX
Breast Cancer Res; 2011 Jun; 13(3):R65. PubMed ID: 21689417
[TBL] [Abstract][Full Text] [Related]
14. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
[TBL] [Abstract][Full Text] [Related]
15. The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line.
Matsui TA; Sowa Y; Murata H; Takagi K; Nakanishi R; Aoki S; Yoshikawa M; Kobayashi M; Sakabe T; Kubo T; Sakai T
Int J Oncol; 2007 Oct; 31(4):915-22. PubMed ID: 17786325
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
17. Characterization of STAT3 activation and expression in canine and human osteosarcoma.
Fossey SL; Liao AT; McCleese JK; Bear MD; Lin J; Li PK; Kisseberth WC; London CA
BMC Cancer; 2009 Mar; 9():81. PubMed ID: 19284568
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
19. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
Tan M; Li P; Klos KS; Lu J; Lan KH; Nagata Y; Fang D; Jing T; Yu D
Cancer Res; 2005 Mar; 65(5):1858-67. PubMed ID: 15753384
[TBL] [Abstract][Full Text] [Related]
20. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
